302 related articles for article (PubMed ID: 34347881)
21. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
22. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.
Frechen S; Junge L; Saari TI; Suleiman AA; Rokitta D; Neuvonen PJ; Olkkola KT; Fuhr U
Clin Pharmacokinet; 2013 Sep; 52(9):763-81. PubMed ID: 23653047
[TBL] [Abstract][Full Text] [Related]
23. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
[TBL] [Abstract][Full Text] [Related]
24. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
[TBL] [Abstract][Full Text] [Related]
25. Global Risdiplam Compassionate Use Program for Patients with Type 1 or 2 Spinal Muscular Atrophy.
Kantaria R; Baker K; Beckley-Kartey S; Gorni K; Montrocher-Ober I; Vindevoghel L
Clin Ther; 2024 Apr; 46(4):374-378. PubMed ID: 38461122
[TBL] [Abstract][Full Text] [Related]
26. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
[TBL] [Abstract][Full Text] [Related]
27. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
[TBL] [Abstract][Full Text] [Related]
28. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Chen KF; Chan LN; Lin YS
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
[TBL] [Abstract][Full Text] [Related]
29. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
[TBL] [Abstract][Full Text] [Related]
30. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.
Kwon JM; Arya K; Kuntz N; Phan HC; Sieburg C; Swoboda KJ; Veerapandiyan A; Assman B; Bader-Weder S; Dickendesher TL; Hansen J; Lin H; Yan Y; Rao VK;
Ann Clin Transl Neurol; 2022 Jun; 9(6):810-818. PubMed ID: 35567422
[TBL] [Abstract][Full Text] [Related]
31. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Stader F; Battegay M; Marzolini C
Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
33. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
34. Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the
Fowler S; Brink A; Cleary Y; Günther A; Heinig K; Husser C; Kletzl H; Kratochwil N; Mueller L; Savage M; Stillhart C; Tuerck D; Ullah M; Umehara K; Poirier A
Drug Metab Dispos; 2022 Jan; 50(1):65-75. PubMed ID: 34620695
[TBL] [Abstract][Full Text] [Related]
35. Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
[TBL] [Abstract][Full Text] [Related]
36. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
[TBL] [Abstract][Full Text] [Related]
37. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
[TBL] [Abstract][Full Text] [Related]
38. Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.
Salerno SN; Edginton A; Gerhart JG; Laughon MM; Ambalavanan N; Sokol GM; Hornik CD; Stewart D; Mills M; Martz K; Gonzalez D;
Clin Pharmacol Ther; 2021 Jan; 109(1):253-262. PubMed ID: 32691891
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.
Bergagnini-Kolev M; Kane K; Templeton IE; Curran AK
AAPS J; 2023 Jun; 25(4):62. PubMed ID: 37344751
[TBL] [Abstract][Full Text] [Related]
40. Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.
Ueno T; Miyajima Y; Landry I; Lalovic B; Schuck E
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):455-466. PubMed ID: 33704920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
